- Protocol Short Name and Number: FRONTIER, 2501
- Protocol Long Name: Phase II Multicenter Trial of MB-CART2019.1 (Zamtocabtagene Autoleucel) Therapy as Frontline Consolidation for High-Risk Mantle Cell Lymphoma
- Protocol Synopsis
- FAQs
- Key Personnel
- BMT CTN #2501 Co-Chair: Nirav Shah, MD, MS
- BMT CTN #2501 Co-Chair: Michael Jain, MD, PhD
- BMT CTN #2501 Protocol Officer: Othman Akhtar, MD
- BMT CTN #2501 Protocol Coordinator: bmtctn2501@emmes.com
- Keywords: Mantle Cell Lymphoma, MCL, CAR-T, CART